Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25 January 2011 to 24 March 2011
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted to OECD, EU and EPA test guidelines in compliance with GLP and reported with a valid GLP certificate.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5395 (In Vivo Mammalian Cytogenetics Tests: Erythrocyte Micronucleus Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: ICH Guidance S2A: Guidance on Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals, 1996
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: ICH Guidance S2B: Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals, 1997
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- micronucleus assay
Test material
- Details on test material:
- Name: Reactive Orange F08-0314
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Wistar RJHan:WI
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Species and strain: Wistar RJHan:WI rats
Source: Laboratoire Elevage Janvier, B.P. 4105, Route des Chênes Secs, 53940 Le Genest-St-Isle CEDEX France
Hygienic level: SPF at arrival; standard laboratory conditions during the study
Justification of species/strain: The rat is regarded as suitable species for toxicology and reproduction studies. Wistar rat was selected due to experience with this strain of rat in toxicity and reproduction toxicity studies and known fertility.
Number of animals: Main groups: 48 male, 48 female rats, 12 animals/sex/group, 4 groups; a sufficient number of at least 8 pregnant females/group was achieved. Recovery groups: 10 male, 10 female rats, 5 animals/sex/group, 2 groups, Control and High dose. Positive Control MNT group: 12 male and 12 female rats, 1 group. At the completion of the study, the spare animals were returned to LAB Research Ltd. spare colony, as their use was not required (no replacements with spare animals were performed).
Age of animals: Young adult rats, approximately 11-12 weeks old at starting and 13-14 weeks at mating. The age range within the study was kept to the minimum practicable.
Body weight range: Males: 397 g – 463 g, Females: 229 g- 273 g; did not exceed ± 20% of the mean weight for each sex at onset of treatment
Acclimation period: At least 7 days (7 days from animal arrival to pre-treatment ophthalmoscopy examination, 12 days to onset of treatment)
Husbandry
Animal health: Only healthy animals were used for the test, as certified by the veterinarian. Females were nulliparous and non-pregnant.
Room number: 524
Cage type: Type II and/or III polypropylene/polycarbonate
Bedding: Lignocel® Hygienic Animal Bedding produced by J. Rettenmaier & Söhne GmbH+Co.KG (Holzmühle 1, D-73494 Rosenberg, Germany). Details of bedding quality are reported.
Light: 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Temperature: 19.6-23.6°C
Relative humidity: 31 - 62%
Ventilation: 15-20 air exchanges/hour
Housing/Enrichment: Rodents were group-housed, up to 5 animals of the same sex and dose group/cage, with the exception of the mating and gestation/delivery period, when they were paired or individually housed, respectively. Group housing allowed social interaction and the deep wood sawdust bedding allowed digging and other normal rodent activities (i.e. nesting).
The temperature and humidity were measured twice daily; no deviations from the target ranges were noted during the study.
Food and water supply
Animals received ssniff® SM R/M-Z+H "Autoclavable complete feed for rats and mice – breeding and Maintenance" produced by ssniff Spezialdiäten GmbH, D-59494 Soest Germany ad libitum, and tap water from municipal supply, as for human consumption from 500 ml bottle ad libitum.
Water quality control analysis is performed once every three months and microbiological assessment is performed monthly by Veszprém County Institute of State Public Health and Medical Officer Service (ÁNTSZ, H-8201 Veszprém, József A.u.36., Hungary).
The food and water are considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study.
Animal identification
Each parental animal (P Generation) was identified by a number unique within the study, written with indelible ink on the tail and cross-referenced to the Animal Master File at LAB Research Ltd. This number consisted of 4 digits, the first digit being the group number, the second, 0 for the males and 5 for the females, and the last 2, the animal number within the group.
The boxes were arranged in such a way that possible effects due to cage placement were minimized and were identified by cards showing the study code, sex, dose group, cage number and individual animal numbers, date of mating and delivery.
Randomization
All parental (P) male and female animals were sorted according to body weight by computer and divided to weight ranges. An equal number of animals from each weight group was randomly assigned to each dose group to ensure that test animals were as nearly as practicable of a uniform weight. The grouping was controlled by SPSS/PC software according to the actual body weight, verifying the homogeneity/variability between/within the groups and cages. Males and females were randomized separately.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- Name: Distilled, sterile water for injection, PhEUR
Lot No.: 3590210, 7530810, 8490910
Manufacturer: TEVA Pharmaceutical Corporation
Expiry Date: February 2013, August 2013, September 2013 respectively
Storage: Room temperature - Details on exposure:
- The test item was formulated in distilled, sterile water for injection at 6.25, 25 and 100 mg/mL concentrations without correction for purity, in the Central Dispensary of LAB Research Ltd. Formulations were prepared and stored refrigerated at 2-8ºC pending use within 7 days.
Rationale for dose selection and route of administration
The dose levels were selected by the Sponsor in consultation with the Study Director based on available data and information from previous experimental work, including the results of an acute oral toxicity study (LAB study code 10/296-001P) and a repeated dose range finding study in the rat (LAB study code 10/296-220PE), with the aim of inducing toxic effects but ideally no death or suffering at the highest dose and a NOAEL at the lowest dose. The oral route was selected as it is a possible route of exposure to the test item in humans.
Test item or Control (water)-treated Groups 1-4 Main animals were administered the dosing solutions daily on a 7 days/week basis, by oral gavage using a tipped gavage needle attached to a syringe. A constant volume was administered to all animals. The actual volume administered was calculated and adjusted based on each animal’s most recent body weight. Dosing of both sexes began after at least 7 days acclimation (A) and 12 days after the animal arrival; the animals were dosed for 2 weeks before mating, during the mating/post-mating, and were continued up to and including the day of necropsy. - Duration of treatment / exposure:
- Males were dosed for at least 28 days (14 days pre-mating, 14 days mating/post-mating period and on the day of necropsy), then were euthanized and subjected to necropsy examination, as no additional mating was considered required.
Females were dosed for 14 days pre-mating, for up to 6 days mating period, through gestation and up to and including the day of necropsy (at least 4 days post-partum dosing). The day of birth (viz. when parturition was complete) is defined as Day 0 post-partum. Females showing no-evidence of copulation were sacrificed as practical, 27-28 days after the end of the mating period.
Positive Control MNT animals
Group 5 animals were mated and females allowed to deliver, similarly to the Main animals. All animals were treated with 20 mg/kg bw/day Cyclophosphamide, administered by intraperitoneal injection approximately 24 h prior to scheduled necropsy (males, on Day 27 for necropsy on Day 28; females, on PND4 for necropsy on PND5).
Recovery animals
Additional 5 male and 5 female rats from the Control and High dose Recovery Groups 1 and 4 scheduled for follow-up observations were not mated, but treated up to the first scheduled euthanasia of the Main dams (Day 41), then kept at least for 14 days without treatment to detect delayed occurrence, or persistence of, or recovery from toxic effects, and subjected to necropsy with macroscopic examination on Day 56. - Frequency of treatment:
- Once daily, 7 days per week
- Post exposure period:
- Main animals were treated with test item up to euthanasia.
Recovery animals were kept for at least 14 days without treatment prior to euthanasia.
Positive control animals were euthanised approximately 24 hours after administration of cyclophosphamide.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0 (control), 62.5, 250 and 1000 mg/kg bw/day
Basis:
nominal in water
- No. of animals per sex per dose:
- Main groups: 48 male, 48 female rats, 12 animals/sex/group, 4 groups
Recovery groups: 10 male, 10 female rats, 5 animals/sex/group, 2 groups, Control and High dose
Positive Control MNT group: 12 male and 12 female rats, 1 group - Control animals:
- yes, concurrent vehicle
- other: Positive control: cyclophosphamide
- Positive control(s):
- A Positive Control group for the Mammalian Erythrocyte Micronucleus Test (MNT) was added. The animals were mated and females allowed to deliver, similarly to the Main animals, then treated once with 20 mg/kg bw Cyclophosphamide, administered by intraperitoneal injection approximately 24 h prior to scheduled necropsy, males, on Day 27 for necropsy on Day 28; females, on PND4 for necropsy on PND5.
For the Positive Control (MNT) Group 5, Cyclophosphamide was dissolved in 0.9% NaCl solution shortly before administration, to obtain a dose concentration of 10 mg/mL for a dose volume of 2 mL/kg; no dose formulation analysis was performed.
Name: Cyclophosphamide monohydrate
Lot number: 079K1569
Supplier: Sigma-Aldrich Co.
Retest/Expiry date: July 2012
Storage condition: Refrigerated (2-8 °C)
Purpose of use: Positive Control item Group 5
Name: Physiological saline (0.9% NaCl solution)
Lot number: 3390210
Supplier: TEVA Gyógyszergyár ZRT
Retest/Expiry date: February 2013
Storage condition: Room temperature
Examinations
- Tissues and cell types examined:
- Four sets of bone marrow smears for MNT were prepared from the animals, including the Vehicle Control (water) and the Positive Control (Cyclophosphamide) groups. The bone marrow was collected from the right femur of the rats immediately after euthanasia (the left femur of Main and Recovery group animals was used for routine histopathology, the left femur of Positive Control animals was discarded) and flushed with foetal bovine serum (5 mL) using a syringe and needle.
- Details of tissue and slide preparation:
- Cells were concentrated by a gentle centrifugation. Smears of the cell pellet were made on standard microscope slides and the slides were then air-dried at room temperature for approximately 24 hours. Dried slides were fixed in methanol for at least 5 minutes and allowed to air-dry.
A set of Giemsa-stained slides was given unique code numbers for blinded evaluation (the code labels covered all unique identification markings on the slides to ensure that they were scored without bias). All slides were blinded; only those of the Control (Gr. 1), Positive Control (Gr. 5) and High dose (Gr. 4) Main animals were sent for evaluation.
2000 polychromatic (immature) erythrocytes (PCEs) were scored per animal to assess the incidence of the micronucleated (MN) cells. The proportion of immature among total (immature + mature) erythrocytes was determined for each animal by counting a total of at least 1000 cells (immature erythrocytes, PCEs plus mature normochromatic erythrocytes, NCEs), in which the number of micronuclei was recorded in both types of erythrocytes.
Criteria for Identification of Micronucleated Erythrocytes
A micronucleus is defined in following way:
- A bluish mauve strongly coloured uniform round or oval particle in the cell.
- The particle should be large enough for the colour to be recognisable, and it should be located inside the cells. Areas with micronucleus-like particles outside the cells should not be used for analysis.
- During focusing, the particle should stay uniform in colour /light refraction and shape within a large interval and focus in the same plane as the erythrocyte.
- The unit of damage is deemed to be the cell, and therefore cells with two or more micronuclei will be counted as single micronucleated cells.
The Micronucleus Test is considered acceptable/valid in the conditions of this study, as it met the following criteria:
- the frequencies of micronucleated polychromatic erythrocytes found in the negative and /or solvent controls fell within the range of historical laboratory control data.
- the positive control item produced biologically relevant increases in the number of micronucleated polychromatic erythrocytes.
- each treated and control group included at least 5 analysable animals. - Evaluation criteria:
- Criteria for a positive response: The test item is considered to have shown genotoxic activity if statistically significant increases in the frequency of micronucleated polychromatic erythrocytes are observed in treated animals compared to the corresponding negative controls, and the increases are dose-related.
Criteria for a negative response: The test item is concluded to have given a negative response if no reproducible, statistically significant increases are observed above the concurrent and historical control values.
Equivocal response: It may be necessary to perform further investigations or to score additional cells if equivocal results are obtained which do not meet the criteria for a positive or negative response. In this study there were no equivocal results, therefore no additional scoring was required. - Statistics:
- Data were collected by completing a pre-prepared sheet by hand. The data were tabulated using appropriate forms for reporting. The frequencies of micronucleated polychromatic erythrocytes in animals in the test groups were compared to the values found in the corresponding negative control group. Statistical analysis was performed using Kruskal Wallis Non Parametric ANOVA test (level of significance 5%). Statistical analysis of the positive control data was not necessary as all values were higher than any of the corresponding negative control values.
Results and discussion
Test results
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- The data were examined for treatment-related effects, and to determine whether further treatment doses would need to be examined. The results of the evaluation of the High dose Main animals indicated that no further analysis was necessary, as no potentially test item related effects were noted at 1000 mg/kg bw/day.
No statistical analysis of the frequencies of micronuclei in the animals treated with the high dose in either males or females was appropriate as the average number of micronuclei was lower than the corresponding negative controls in both cases. The evaluation thus showed a clear negative result for the test item at 1000 mg/kg bw/day in both sexes, thus, no further slide examination was considered required.
4/12 of the positive control males had fewer than 10 micronuclei; however, statistical comparison between the negative and positive male controls gave a value of H = 16.691 (p<0.001). Although one female treated with the negative control had a value of 11, the lowest positive control value was 16 and the average frequency was 47. Statistical comparison between the negative and positive female controls gave a value of H = 17.384 (p<0.001), indicating a strong response in both the positive control groups.
Any other information on results incl. tables
The individual and mean data are presented in Tables 1 – 6 below.
TABLE 1: DOSE GROUP - CONTROL MALES
Animal code |
Slide code |
Micronucleated PCE/2000 PCE |
PCE/1000 PCE+NCE |
1001 |
23 |
5 |
430 |
1002 |
50 |
0 |
346 |
1003 |
13 |
4 |
364 |
1004 |
46 |
5 |
375 |
1005 |
17 |
5 |
354 |
1006 |
1 |
1 |
319 |
1007 |
27 |
4 |
380 |
1008 |
30 |
2 |
387 |
1009 |
6 |
3 |
342 |
1010 |
39 |
2 |
352 |
1011 |
36 |
4 |
409 |
1012 |
57 |
3 |
332 |
Mean |
|
3.167 |
365.83 |
SD |
|
1.642 |
32.12 |
TABLE 2: DOSE GROUP - HIGH DOSE 1000 mg/kg bw/day MALES
Animal code |
Slide code |
Micronucleated PCE/2000 PCE |
PCE/1000 PCE+NCE |
4001 |
20 |
5 |
435 |
4002 |
25 |
1 |
356 |
4003 |
10 |
2 |
421 |
4004 |
41 |
3 |
440 |
4005 |
14 |
2 |
397 |
4006 |
43 |
1 |
336 |
4007 |
56 |
1 |
390 |
4008 |
4 |
3 |
395 |
4009 |
54 |
3 |
377 |
4010 |
32 |
4 |
434 |
4011 |
48 |
1 |
272 |
4012 |
37 |
5 |
424 |
Mean |
|
2.583 |
389.75 |
SD |
|
1.505 |
49.37 |
TABLE 3: DOSE GROUP - CYCLOPHOSPHAMIDE MALES
Animal code |
Slide code |
Micronucleated PCE/2000 PCE |
PCE/1000 PCE+NCE |
5001 |
15 |
21 |
290 |
5002 |
33 |
5 |
216 |
5003 |
5 |
9 |
353 |
5004 |
42 |
16 |
185 |
5005 |
59 |
19 |
280 |
5006 |
24 |
6 |
179 |
5007 |
55 |
6 |
231 |
5008 |
9 |
20 |
368 |
5009 |
40 |
12 |
238 |
5010 |
49 |
15 |
261 |
5011 |
19 |
29 |
338 |
5012 |
28 |
13 |
256 |
Mean |
|
14.25 |
266.25 |
SD |
|
7.25 |
62.30 |
TABLE 4: DOSE GROUP - CONTROL FEMALES
Animal code |
Slide code |
Micronucleated PCE/2000 PCE |
PCE/1000 PCE+NCE |
1501 |
89 |
4 |
502 |
1502 |
103 |
6 |
482 |
1503 |
73 |
7 |
483 |
1504 |
120 |
7 |
528 |
1505 |
78 |
11 |
536 |
1506 |
115 |
3 |
542 |
1507 |
95 |
2 |
438 |
1508 |
63 |
10 |
500 |
1509 |
108 |
2 |
508 |
1510 |
84 |
2 |
501 |
1511 |
66 |
2 |
465 |
1512 |
101 |
3 |
466 |
Mean |
|
4.917 |
495.92 |
SD |
|
3.232 |
30.97 |
TABLE 5: DOSE GROUP - HIGH DOSE 1000 mg/kg bw/day FEMALES
Animal code |
Slide code |
Micronucleated PCE/2000 PCE |
PCE/1000 PCE+NCE |
4501 |
92 |
4 |
428 |
4502 |
70 |
4 |
521 |
4503 |
98 |
1 |
409 |
4504 |
75 |
4 |
435 |
4505 |
106 |
3 |
449 |
4506 |
81 |
4 |
458 |
4507 |
87 |
8 |
535 |
4508 |
112 |
3 |
555 |
4509 |
65 |
5 |
531 |
4510 |
104 |
1 |
451 |
4511 |
79 |
4 |
517 |
4512 |
118 |
3 |
443 |
Mean |
|
3.667 |
477.67 |
SD |
|
1.826 |
50.14 |
TABLE 6: DOSE GROUP - CYCLOPHOSPHAMIDE FEMALES
Animal code |
Slide code |
Micronucleated PCE/2000 PCE |
PCE/1000 PCE+NCE |
5501 |
80 |
16 |
394 |
5502 |
105 |
44 |
416 |
5503 |
117 |
59 |
538 |
5504 |
119 |
16 |
442 |
5505 |
64 |
33 |
493 |
5506 |
111 |
47 |
410 |
5507 |
74 |
58 |
476 |
5508 |
97 |
32 |
462 |
5509 |
99 |
24 |
405 |
5510 |
69 |
97 |
436 |
5511 |
91 |
102 |
455 |
5512 |
86 |
36 |
522 |
Mean |
|
47.00 |
459.08 |
SD |
|
28.271 |
43.70 |
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): negative
In conclusion, no induction of micronuclei in bone marrow erythrocytes was observed following administration of Reactive Orange F08-0314 to Wistar rats daily by oral gavage to the High dose Main animals at 1000 mg/kg bw/day, thus, there was no evidence of any genotoxic activity of the test item under the conditions of this study. - Executive summary:
The objective of this study was to assess the potential genotoxic effect of the test item by examining the induction of micronuclei in bone marrow erythrocytes of treated and control animals.
This study was conducted to OECD, EU and EPA test guidelines in compliance with GLP and reported with a valid GLP certificate.
In conclusion, no induction of micronuclei in bone marrow erythrocytes was observed following administration of Reactive Orange F08-0314 to Wistar rats daily by oral gavage to the High dose Main animals at 1000 mg/kg bw/day, thus, there was no evidence of any genotoxic activity of the test item under the conditions of this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Kuigi ECHA veebilehe paljud osad on sinu keeles olemas, on see leht osaliselt inglise keeles. Lisateave ECHA mitmekeelsuse kohta.
Tere tulemast Euroopa Kemikaaliameti (ECHA) veebilehele! Internet Explorer 7 (ja varasemad versioonid) ei toeta täielikult seda veebilehte. Uuendage oma Internet Exploreri versiooni.
Sellel veebilehel kasutatakse küpsiseid, et tagada lehe parim kasutus.
Lisateave küpsiste kohta.